Showing 1961-1970 of 3134 results for "".
- Systematic Review Examines Vaginal Laser and Radiofrequency for Stress Urinary Incontinencehttps://modernaesthetics.com/news/systematic-review-examines-vaginal-laser-and-radiofrequency-for-stress-urinary-incontinence/2486518/In a systematic review and meta-analysis published in International Urogynecology Journal, investigators reported that energy-based devices may offer modest short-term symptom improvement for women with stress urinary incontinence compared with sham treatment. David Lukanović, Gee
- Case Report Describes Dual-Phase CL Code for Facial Rejuvenationhttps://modernaesthetics.com/news/case-report-describes-dual-phase-cl-code-for-facial-rejuvenation/2486484/A case report in the April 2026 issue of Journal of Cosmetic Dermatology described a dual-phase injectable approach to facial rejuvenation that combined contour restoration with ligamentous support using a polycaprolactone-based collagen stimulator. The authors termed the method the “CL
- AAD 2026: New Study Highlights Dual-Action Antioxidant Serum for UV-Induced Skin Protectionhttps://modernaesthetics.com/news/aad-2026-new-study-highlights-dual-action-antioxidant-serum-for-uv-induced-skin-protection/2486463/New research presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting highlights the potential of a multifunctional antioxidant serum, AOX2.0, to protect human skin from ultraviolet (UV)-induced damage while supporting epidermal recovery. The study examined how oxidative stress
- AAD 2026: Allergan Aesthetics Highlights TrenibotE Data and GLP-1 RA Patient Trendshttps://modernaesthetics.com/news/aad-2026-allergan-aesthetics-highlights-trenibote-data-and-glp-1-patient-trends/2486432/Allergan Aesthetics, an AbbVie company, presented four posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, including new findings on repeat treatment with investigational trenibotulinumtoxinE (TrenibotE) and insights into aesthetic trends among patients r
- AAD 2026: RelabotulinumtoxinA Shows Consistent Efficacy Across Age Groupshttps://modernaesthetics.com/news/aad-2026-relabotulinumtoxina-shows-consistent-efficacy-across-age-groups/2486431/A post hoc analysis presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated the impact of age on outcomes with relabotulinumtoxinA in patients with moderate-to-severe glabellar lines (GLs) and lateral canthal lines (LCLs). The analysis pooled data
- AAD 2026: Survey Highlights Facial Concerns Among GLP-1 Weight Loss Patientshttps://modernaesthetics.com/news/aad-2026-survey-highlights-facial-concerns-among-glp-1-weight-loss-patients/2486397/A large survey presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, highlights evolving aesthetic concerns among patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. The analysis, based on responses from 406 US healthcare
- AAD 2026: Oral Supplement Shows Gains in Hair Strength, Collagen VIIhttps://modernaesthetics.com/news/aad-2026-oral-supplement-shows-gains-in-hair-strength-collagen-vii/2486396/New data presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, evaluated a nutraceutical approach to improving hair strength through collagen VII upregulation and mechanical resistance outcomes. The study assessed a daily oral supplement containing turmer
- AAD 2026: Revance to Showcase Expanding Aesthetics Portfoliohttps://modernaesthetics.com/news/aad-2026-revance-to-showcase-expanding-aesthetics-portfolio/2486383/Revance Therapeutics Inc. announced it will showcase its expanding portfolio of aesthetics, regenerative medicine, and consumer skincare products at the 2026 American Academy of Dermatology (AAD) Annual Meeting, scheduled for March 26–31 in Denver, Colorado. The company plans a series of in-booth
- FDA Clears Full-Wavelength Capability for Lasermach Laser Systemhttps://modernaesthetics.com/news/fda-clears-full-wavelength-capability-for-lasermach-laser-system/2486382/Wingderm announced that its Lasermach laser system has received expanded clearance from the US Food and Drug Administration (FDA), enabling use across all 3 wavelengths—755 nm, 808 nm, and 1064 nm. The update includes clearance for a mixed-wavelength handpiece combining all 3 wavelengths, as well
- AAD 2026: Acclaro to Highlight Expanding Clinical Uses of UltraClear 2910 nm Fiber Laserhttps://modernaesthetics.com/news/aad-2026-acclaro-to-highlight-expanding-clinical-uses-of-ultraclear-2910-nm-fiber-laser/2486381/Emerging clinical data on Acclaro’s UltraClear® 2910 nm fiber laser is set to be presented during multiple sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado from March 26 through 31. The technology, a cold ablative fiber lase